Products & Solutions
Back
Products & Solutions
Core Disciplines
Chemistry Immunoassay Hematology Urinalysis Microbiology Blood Banking Protein Chemistry
Workflow & Informatics
Automation Systems Clinical Information Management Tools PROService Remote Service Tool DxONE Inventory Manager Instrument Aggregator Middleware Data Analytics
Solutions For
SARS-CoV-2 Antibody Testing Anemia Cardiovascular Disease Diabetes Diagnostics Drug Monitoring & Detection Prostate Cancer Detection Reproductive Health Sepsis Life Sciences ›
Service promo banner
Support
Back
Support
Account Support
Create Account Manage Account Settings View All Account Support
Product Support
DxS Service In Vitro Diagnostic Regulation (IVDR) Manage My Technical Documents Search for Technical Documents Safety Data Sheets (SDS/MSDS) Technical Documents Overview Manage My Regulatory Notifications Manage My Warranties & Agreements Request Instrument Support View Services Information View All Product Support
Ordering Support
Order Status & Tracking Track My Invoices View Return/RMA Policy Get Help with Orders View All Ordering Support
Resources
Back
Resources
Product Training
Training Courses › Register for Training ›
Education & Research
Webinars Posters 3D Virtual Laboratory Showcase
Insights
Clinical Studies & Trends Case Studies Publications
Lab order management systems
Company
Back
Company
People & Culture
Overview Meet Our Teams Diversity + Inclusion How We Work Innovation
Careers
Job Search › Career Stories Programs & Grants Office Locations
News & Events
Awards & Recognition Newsroom Blog Events Calendar
Home / Clinical Laboratory Diagnostic Products and Solutions / Immunoassay / Access BNP & NT-proBNP Assays
Access BNP Assay

Access BNP & NT-proBNP Immunoassays

Natriuretic peptides reflect cardiac status and effects of therapy

Access BNP and NT-proBNP immunoassays are used to aid in the diagnosis of heart failure and left ventricular dysfunction.1
B‐type natriuretic peptide (BNP) is a cardiac hormone originating in the heart.2 In patients with heart failure, BNP and NT-proBNP levels are elevated.3 They can be assessed as important measures of cardiac function and diagnosis of heart failure.4

This product may not be available in your country or region at this time. Please contact your Beckman Coulter sales representative or distributor for more information.
Request more info Added Error
Overview
Specifications
Documents
Videos
Overview Specifications Documents Videos
All
Overview
Specifications
Documents
Videos

Efficiently support diagnosis and assessment of heart failure severity with trustworthy results

B-type natriuretic peptide (BNP) and the N-terminal pro hormone BNP (NT-proBNP) are well established for use in diagnosis of heart failure. Following production, the prohormone is cleaved at a 1:1 ratio into NT-proBNP and BNP. (Fig. 1) BNP is involved in regulating blood volume.2 Blood levels of NT-proBNP and BNP increase when the left ventricle is stretched, as occurs during heart failure, a condition where the heart cannot pump enough blood.

Natriuretic peptides play a significant role in controlling cardiovascular function. The biologically active BNP ring is involved in cardiorenal homeostasis by stimulating diuresis and natriuresis. Both NT-proBNP and BNP biomarkers provide demonstrated benefit for heart failure patients in emergency and outpatient settings. Both NT-proBNP and BNP are included in standard of care guidelines for both the American College of Cardiology/American Heart Association5 and European Society of Cardiology.6

Laboratories can help clinicians deliver patient care with confidence for all stages of heart failure with Access NT-proBNP and BNP assays, highly sensitive and specific assays that aid clinicians in heart failure diagnosis, assessment of severity, and risk stratification.

Access BNP Cardiac
Figure 1. BNP and NT-proBNP production in the ventricular cardiac myocardium7

 

NT-proBNP
Increase accuracy in diagnosing heart failure with age-based cutoffs that improve specificity by 31% compared with a single cutoff strategy and specific information that supports interpretation of results in patients with comorbidities.
  • Results in under 11 minutes
  • Limit of Detection (LoD) ≤10 ng/L
  • Sample stability for 72 hours at room temperature
  • Compatible with serum, LiHep and EDTA plasma

BNP
Advance patient care with a strong predictor of clinical outcomes that supports diagnosis and assessment of severity for congestive heart failure and risk stratification of those with acute coronary syndrome.
  • Measures active hormone
  • General specificity of 98% using a threshold of 100 pg/mL
  • Total observed imprecision <7%
  • Analytical sensitivity: 1 pg/mL (95% confidence)

The Access NT-proBNP and BNP assays are not intended to be used in isolation; results should be interpreted in conjunction with other diagnostic tests and clinical information.

BNP NT-proBNP

Analytical Measuring Range

 1 to 5000 pg/mL 10 to 35,000 ng/L (pg/mL)

Sample Type/Size

 Plasma (EDTA) Serum, lithium heparin plasma, and EDTA

Time to First Result

 ≥16.2 minutes <11 minutes

Analytical Sensitivity

 1 pg/mL (95% confidence)

Limit of Detection (LoD) ≤10 ng/L (pg/mL)

20% CV Limit of Quantitation (LoQ) ≤10 ng/L (pg/mL)

Calibrator Levels

 0, and approximately 25, 100, 500, 2500, and 5000 pg/mL 0, and approximately 25, 100, 500, 2500, and 5000 pg/mL

Open pack stability

 28 days 61 days

Calibration stability

 28 days 28 days

Total Imprecision

 <7% ≤4.0 ng/L (pg/mL) SD at concentrations ≤50 ng/L (pg/mL)
≤8.0% CV at concentrations >50 ng/L (pg/mL)

BNP & NT-proBNP Technical Bulletins

Triage BNP Technical Bulletin - Biotin Interference
This important information pertains to the Quidel Triage BNP Test for the Beckman Coulter® Access Family of Immunoassay Systems (Triage BNP for BCIS).

Access BNP Technical Bulletin – Biotin Interference
This important information pertains to the Access BNP test for the Access Family of Immunoassay Systems
Sort
Relevance
Relevance
Document Title A-Z
Document Title Z-A
Item/Ref No.
Release Date (Newest)
Release Date (Oldest)

View all documents

Q&A: Natriuretic Peptides 101

In this video series, Drs. Robert Christenson and W. Frank Peacock share their perspectives from the lab and Emergency Department on the value of BNP and NT-proBNP testing. Learn as they discuss the biology, clinical value, and confounding factors associated with BNP and NT-proBNP tests and how they are used in heart failure diagnostics and therapeutic monitoring.

Speakers:

Robert Christenson, PhD, DABCC, FAACC, FACC
Professor of Pathology & Professor of Medical and Research Technology
University of Maryland School of Medicine

 
Frank Peacock

W. Frank Peacock IV, MD, FACEP, FACC, FESC
Professor of Emergency Medicine and Vice Chair of Research for the Department of Emergency Medicine
Baylor College of Medicine

Video Key considerations when deciding between BNP and NT-proBNP

Watch video

Video Importance of turnaround time for cardiac STAT assays

Watch video

Video Considerations for interpreting natriuretic peptide values

Watch video

Video Importance of reference intervals

Watch video

Video Considerations for comorbidities when interpreting natriuretic peptide results

Watch video

Video The future of heart failure diagnostics

Watch video

Video The impact of clinical decision support and artificial intelligence-related technologies on heart failure risk assessment

Watch video

Immunoassay Analyzers

Access 2 Immunoassay Analyzer

Access 2 Analyzer

Reliability matters. This benchtop immunoassay analyzer fits labs with space constraints and delivers fast, reliable results.

Learn more
UniCel DxI 600 Immunoassay Analyzer

DxI 600 Analyzer

Simplicity matters. This immunoassay analyzer gives technologists the benefit of ease of use without sacrificing throughput.

Learn more
UniCel DxI 800 immunoassay analyzer

DxI 800 Analyzer

Scalability matters. This immunoassay system supports the expanding needs of your growing laboratory.

Learn more
NEW
DxI 9000

DxI 9000 Analyzer

Time matters. Create time for what matters most with a precise, high-volume analyzer with ZeroDaily maintenance.

Learn more

References:

1. Bionda C, Bergerot C, Ardail D, Rodriguez-Lafrasse C, Rousson R. Plasma BNP and NT-proBNP assays by automated immunoanalyzers: analytical and clinical study. Ann Clin Lab Sci. 2006;36(3):299-306.

2. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart. 2006;92(6):843-849. doi:10.1136/hrt.2005.071233

3. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-239. doi:10.1016/j.jacc.2013.05.019

4. Chien T-I, Chen H-H, Kao J-T. Comparison of Abbott AxSYM and Roche Elecsys 2010 for measurement of BNP and NT-proBNP. Clin Chim Acta. 2006;369(1):95-99. doi:10.1016/j.cca.2006.01.017

5. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e876-e894. doi:10.1161/CIR.0000000000001062

6. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368

7. Kim YS, Karisa N, Jeon WY, Lee H, Kim Y-C, Ahn J. High-level production of N-terminal pro-brain natriuretic peptide, as a calibrant of heart failure diagnosis, in Escherichia coli. Appl Microbiol Biotechnol. 2019;103(12):4779-4788. doi:10.1007/s00253-019-09826-8


Products
Support
Company Newsletter
Beckman Coulter Life Sciences
Stay Connected
Products
Support
Company
Newsletter
Beckman Coulter Life Sciences
Stay Connected

Information addressed to health professionals. The products presented on this site are for professional use only, and, where applicable, comply with the requirements of the IVD Directive 98/79 / EC. Instructions for use must be consulted before using these products.

 

© 2022 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. All other trademarks are the property of their respective owners.

U.S. Government Users Restricted Rights - As per GSA ADP Schedule Contract with Beckman Coulter, Inc., the use, duplication or disclosure is restricted as follows: Beckman Coulter hereby authorizes user to copy those documents published on the World Wide Web by Beckman Coulter, for noncommercial use, and only within the user's organization. Except as expressly provided above, nothing contained herein shall be construed as granting any license or right under any Beckman Coulter copyright. Nothing contained herein shall be construed as granting by implication, estoppel or otherwise any license or right under any patent or trademark of Beckman Coulter or any third party.